This is an observer-blinded, three-arms study in 376 patients in Chinese individuals aged from 18 to 55 years old who had previously received three doses COVID-19 vaccine. Immunogenicity in terms of ...
Please provide your email address to receive an email when new articles are posted on . A post hoc analysis of phase 3 trial data showed no association of immunogenicity with efficacy or safety for ...
Scientists working for Novartis have taken a step forward in better understanding how new classes of biological drugs might affect patients’ immune systems. Paul Wassmann, PhD senior principal ...
Assessing immunogenicity is a cornerstone of modern drug development, especially for biologics and vaccines. Understanding how the immune system interacts with therapeutic agents is essential to ...
The UK’s MHRA and Regional Ethics Committee have approved Epitopea’s OVACT trial for CryptiVax-1001, an RNA-based vaccine targeting advanced high-grade serous ovarian cancer. The Phase I/Ib study will ...
Background: This study (NCT00383123) compared the immunogenicity and safety of 2 trivalent inactivated influenza vaccines: Fluarix [GlaxoSmithKline (study vaccine)] and Fluzone [Sanofi Pasteur ...
Hepatocellular carcinoma (HCC) is a leading cause of cancer death worldwide, with limited curative options. Tumor vaccines ...
In a recent study published in Scientific Reports, researchers characterized the immunogenicity and safety of poxvirus-based Nipah vaccines that can be used in humans and species responsible for Nipah ...
As biologics and biosimilars continue to reshape oncology, ensuring their safety and efficacy remains a top priority. In this expert-driven report, Cerba Research examines the latest advancements in ...
Symposium brings together global leaders in immunogenicity to connect with China’s rapidly evolving pharmaceutical development landscape Speakers include thought leaders in biotherapeutics, complex ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results